Recent studies have also highlighted the potential of dehydrovomifoliol from Artemisia frigida Willd, a traditional Chinese medicine (TCM), in preventing non-alcoholic fatty liver disease (NAFLD) by influencing hepatic lipogenesis and fatty acid oxidation, identifying E2F1 as a core gene in NAFLD treatment and linking its role to the regulation of the AKT/mTOR signaling pathway [66]. The gene discussed is E2F1; the disease is metabolic dysfunction-associated steatotic liver disease.